KRT18P22: A Potential Drug Target and Biomarker (G442252)

Target Name: KRT18P22

NCBI ID: G442252

KRT18P22

Other Name(s): keratin 18 pseudogene 22 | Keratin 18 pseudogene 22

KRT18P22: A Potential Drug Target and Biomarker

KRT18P22 is a gene that encodes for a protein known as KRT18P22. KRT18P22 is a member of the KRT gene family, which is responsible for the production of proteins that are involved in cell signaling pathways. There are several different isoforms of the KRT18P22 gene, each of which is expressed at different levels in the body.

One of the most interesting aspects of KRT18P22 is its potential as a drug target. KRT18P22 has been shown to play a role in a number of cellular processes, including cell signaling, cell adhesion, and cell survival. It is also involved in the development and progression of a variety of diseases, including cancer.

One of the ways that KRT18P22 is thought to work is by regulating the activity of a protein called TGF-β. TGF-β is a well-known transcription factor that is involved in a wide range of cellular processes, including cell signaling, cell adhesion, and cell survival. It is thought to play a key role in the development and progression of many diseases, including cancer.

KRT18P22 has been shown to interact with TGF-β and to regulate its activity. This suggests that KRT18P22 may be a good candidate for drugs that are designed to target TGF-β. In fact, several studies have shown that KRT18P22 can be used to inhibit the activity of TGF-β and to reduce the growth of cancer cells.

Another way that KRT18P22 is thought to work is by regulating the activity of a protein called PDGF-尾. PDGF-尾 is a well-known transcription factor that is involved in a wide range of cellular processes, including cell signaling, cell adhesion, and cell survival. It is also thought to play a key role in the development and progression of many diseases, including cancer.

KRT18P22 has been shown to interact with PDGF-尾 and to regulate its activity. This suggests that KRT18P22 may be a good candidate for drugs that are designed to target PDGF-尾. In fact, several studies have shown that KRT18P22 can be used to inhibit the activity of PDGF-尾 and to reduce the growth of cancer cells.

In addition to its potential as a drug target, KRT18P22 is also of interest as a biomarker. Because KRT18P22 is expressed at different levels in the body, it can be used as a marker for a variety of diseases, including cancer. This makes it an attractive candidate for use as a diagnostic marker or as a target for targeted therapies.

Overall, KRT18P22 is a gene that has a lot of potential as a drug target and as a biomarker. Further research is needed to fully understand its role in cellular processes and to develop effective treatments based on its properties.

Protein Name: Keratin 18 Pseudogene 22

The "KRT18P22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRT18P22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets